featured
Trastuzumab + Paclitaxel Led to Objective Tumor Responses in Patients With EGFR-Mutated, HER2+ NSCLC After Progression on EGFR–TKIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab and Paclitaxel in Patients With EGFR Mutated NSCLC That Express HER2 After Progression on EGFR TKI Treatment
Br. J. Cancer 2018 Jul 31;[EPub Ahead of Print], AJ de Langen, M Jebbink, SMS Hashemi, JL Kuiper, J de Bruin-Visser, K Monkhorst, E Thunnissen, EF SmitFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.